The ability to quickly update a forecast based on new information is vital. Equinox Group’s unique Competition Module automatically recalculates the patient share any new drug is likely to achieve given new assumptions such as

• a change in expected efficacy
• the emergence of an unforeseen side effect
• a new launch date

A change in these assumptions is easy to enter into an Equinox Group forecast model and is instantly reflected in revised patient shares and revenue streams. Equinox models support rapid sensitivity analysis to reflect the commercial risk of multiple uncertainties.